Idelalisib D5 is the penta-deuterated form of Idelalisib (CAL101, GS1101; CAL-101, GS-1101; Zydelig), which is an approved anticancer drug acting as a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays. Idelalisib is used for the treatment of relapsed chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma and small lymphocytic lymphoma (SLL).

纯度：≥98%

CAS：1830330-31-8